Compare DTI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | IFRX |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 81.3M |
| IPO Year | N/A | 2017 |
| Metric | DTI | IFRX |
|---|---|---|
| Price | $3.45 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 189.5K | ★ 647.2K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,964,000.00 | $73,729.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $1.30 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $1.43 | $0.71 |
| 52 Week High | $3.82 | $2.77 |
| Indicator | DTI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 45.22 |
| Support Level | $2.45 | $1.00 |
| Resistance Level | $3.42 | $1.10 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 99.15 | 15.22 |
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.